We are live on
!
Find out more
Arrowstreet Capital Portfolio holdings
AUM
$185B
1-Year Est. Return
39.58%
This Fund
S&P 500
This Quarter
Est. Return
+1.19%
1 Year Est. Return
+39.58%
3 Year Est. Return
+145.48%
5 Year Est. Return
+192.07%
10 Year Est. Return
+749.68%
AUM
$17.7B
AUM Growth
+$1.44B
(+8.9%)
Cap. Flow
+$1.58B
Cap. Flow
% of AUM
8.95%
Top 10 Holdings %
Top 10 Hldgs %
19.92%
Holding
1,403
New
439
Increased
358
Reduced
346
Closed
241
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$403M |
| 2 |
Walt Disney
DIS
|
+$157M |
| 3 |
CELG
Celgene Corp
CELG
|
+$141M |
| 4 |
Citigroup
C
|
+$137M |
| 5 |
Starbucks
SBUX
|
+$132M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Union Pacific
UNP
|
+$244M |
| 2 |
TWC
TIME WARNER CABLE INC NEW COM STK
TWC
|
+$178M |
| 3 |
Canadian National Railway
CNI
|
+$146M |
| 4 |
AT&T
T
|
+$139M |
| 5 |
Micron Technology
MU
|
+$134M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.11% |
| 2 | Financials | 17.79% |
| 3 | Healthcare | 17.78% |
| 4 | Consumer Staples | 7.98% |
| 5 | Consumer Discretionary | 7.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
United Therapeutics
UTHR
$22.9B
| $9.61M | 0.05% |
55,226
+33,040
| +149% | +$5.94M |
|
|
AMSG
277
DELISTED
Amsurg Corp
AMSG
| $9.56M | 0.05% |
136,639
+9,640
| +8% | +$644K |
|
|
AF
278
DELISTED
Astoria Financial Corporation
AF
| $9.56M | 0.05% |
693,053
-191,847
| -22% | -$2.55M |
|
|
LUX
279
DELISTED
Luxottica Group
LUX
| $9.52M | 0.05% |
143,301
+19,734
| +16% | +$1.31M |
|
280
Emerson Electric
EMR
$87.5B
| $9.45M | 0.05% |
+170,500
| New | +$10M |
|
281
Opko Health
OPK
$985M
| $9.42M | 0.05% |
+585,800
| New | +$9.11M |
|
|
SC
282
DELISTED
SANTANDER CONSUMER USA HOLDINGS INC
SC
| $9.3M | 0.05% |
+363,712
| New | +$8.87M |
|
283
KB Financial Group
KB
$42.6B
| $9.13M | 0.05% |
+277,723
| New | +$10M |
|
284
Mondelez International
MDLZ
$80.1B
| $9.12M | 0.05% |
221,714
-100,327
| -31% | -$3.93M |
|
|
CPHD
285
DELISTED
Cepheid Inc
CPHD
| $9.11M | 0.05% |
148,928
+112,228
| +306% | +$6.4M |
|
286
CEMIG Preferred Shares
CIG
$6.12B
| $9.1M | 0.05% |
4,686,424
+1,776,913
| +61% | +$4.21M |
|
287
Loews
L
$23.7B
| $9.06M | 0.05% |
235,263
+9,347
| +4% | +$380K |
|
288
Prudential
PUK
$34.7B
| $9.03M | 0.05% |
191,640
-10,680
| -5% | -$519K |
|
289
Regis Corp
RGS
$71.9M
| $8.98M | 0.05% |
28,485
-135
| -0.5% | -$45.1K |
|
|
SKX
290
DELISTED
Skechers
SKX
| $8.98M | 0.05% |
245,262
-319,809
| -57% | -$10.3M |
|
291
Bio-Rad Laboratories Class A
BIO
$9.16B
| $8.95M | 0.05% |
59,410
+5,690
| +11% | +$814K |
|
|
FCS
292
DELISTED
FAIRCHILD SEMICONDUCTOR INTL INC COMMON
FCS
| $8.93M | 0.05% |
513,921
+17,220
| +3% | +$330K |
|
|
KING
293
DELISTED
KING DIGITAL ENTMT PLC ORD SHS (IRL)
KING
| $8.93M | 0.05% |
626,456
-267,606
| -30% | -$4.15M |
|
|
ABMD
294
DELISTED
Abiomed Inc
ABMD
| $8.87M | 0.05% |
+135,000
| New | +$8.97M |
|
295
Telkom Indonesia
TLK
$14.8B
| $8.87M | 0.05% |
409,006
+63,796
| +18% | +$1.38M |
|
296
MBIA
MBI
$269M
| $8.85M | 0.05% |
1,472,042
-7,898
| -0.5% | -$71.3K |
|
297
Murphy USA
MUSA
$9.9B
| $8.76M | 0.05% |
156,882
+18,652
| +13% | +$1.17M |
|
298
Sanmina
SANM
$11B
| $8.73M | 0.05% |
433,017
-167,638
| -28% | -$3.66M |
|
299
AbbVie
ABBV
$431B
| $8.7M | 0.05% |
129,481
-297,377
| -70% | -$19.4M |
|
|
NSR
300
DELISTED
Neustar Inc
NSR
| $8.69M | 0.05% |
297,630
+173,569
| +140% | +$4.91M |
|
Similar funds
VGA
Arrowstreet Capital's Q2 2015 Portfolio in Review
As of Q2 2015, Arrowstreet Capital held 1,403 positions worth $17.7B, up 8.9% from $16.2B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Arrowstreet Capital deployed $1.58B of net new capital in Q2 2015, opening 439 new positions and adding to 358 existing holdings. Its largest new stake was Teva Pharmaceuticals: 1,922,584 shares worth $114M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 29% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Union Pacific, an estimated $244M trimmed.
- Arrowstreet Capital's largest Q2 2015 buy was Teva Pharmaceuticals: 1,922,584 shares worth $114M.
- Arrowstreet Capital added most to Apple in Q2 2015, an estimated $403M increase.
- Arrowstreet Capital's biggest Q2 2015 reduction was Union Pacific, cutting an estimated $244M.
- Arrowstreet Capital fully exited Canadian National Railway in Q2 2015, selling an estimated $146M.
- Arrowstreet Capital's ten largest holdings make up 20% of its $17.7B portfolio in Q2 2015.
- Arrowstreet Capital opened 439 new positions and closed 241 in Q2 2015.
- Arrowstreet Capital's portfolio value rose 8.9% quarter-over-quarter to $17.7B.
Based on Arrowstreet Capital's 13F filing for Q2 2015, filed 13 Aug 2015.